Apligraf: Difference between revisions
m decapitalize category names |
m remove <coauthors> parameter |
||
| Line 23: | Line 23: | ||
Organogenesis is presently seeking FDA approval for Apligraph Oral, a foreskin-derived product for the "treatment of surgically treated gingival and alveolar mucosal surface defects in adults."<ref>{{REFnews | Organogenesis is presently seeking FDA approval for Apligraph Oral, a foreskin-derived product for the "treatment of surgically treated gingival and alveolar mucosal surface defects in adults."<ref>{{REFnews | ||
| last= | |last= | ||
| first | |first= | ||
|url=http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM284112.pdf | |||
| url=http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM284112.pdf | |title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript | ||
| title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript | |date=November 2011 | ||
| date=November 2011 | |publisher=FDA | ||
| publisher=FDA | |quote= | ||
| quote= | |accessdate=2011-12-20 | ||
| accessdate=2011-12-20 | |||
}}</ref> | }}</ref> | ||